Orange Grove Bio strives to positively transform the quality of life of patients with cancer, autoimmune and inflammatory diseases by expediting the development of new medical breakthroughs.
“I look forward to contributing my deep expertise in therapeutic development and cancer research to support Orange Grove Bio’s vision of creating biotechnology companies that will develop the transformative medicines of tomorrow.”
– John C. Byrd, M.D., Renowned Cancer Clinician and Researcher, Chair and Professor for the Department of
Internal Medicine at the University of Cincinnati College of Medicine
We focus on partnerships with research institutions and universities which, along with our network of co-investors, operations, and research & development teams, allows us to streamline the technology licensing process and expedite drug development to make a positive impact on patients and their communities.
Direct Sourcing Process
Our university partnerships and close relationships with scientists and clinicians provide us with unique opportunities to identify and license promising biomedical innovation
Comprehensive Diligence Process
A multi-stage process through hypothesizing the clinical and financial efficacy of each asset in conjunction with the Principal Investigator, their team, and Orange Grove Bio’s team of Biology PhDs and venture partners.
Seasoned Operations Teams
Comprised of industry experts, we leverage their decades of expertise in navigating pharmaceutical assets through the clinical process and driving scientific and finance operations.
In The News
Orange Grove Bio Expands Academic Collaboration Activities Internationally Through New Strategic Partnerships
Collaborations with Yonsei University Health System and Pohang University of Science and Technology Designed to Strengthen Biotech Entrepreneurial Ecosystem in South Korea The following excerpt was taken from Globenewswire– continue reading here. Orange Grove Bio Expands Academic Collaboration Activities Internationally Through New Strategic Partnerships CINCINNATI, March 23, 2023 (GLOBE NEWSWIRE) — Orange Grove Bio, a… Continue reading Orange Grove Bio Expands Academic Collaboration Activities Internationally Through New Strategic PartnershipsRead Article
Einstein Hosts Inaugural Therapeutics Venture and Pitch Competition
Einstein Hosts Inaugural Therapeutics Venture and Pitch Competition The following excerpt was taken from Einsteinmed.edu — continue reading here. Scientists, venture investment firm leaders, and industry stakeholders gathered on Tuesday, June 7 to attend Albert Einstein College… June 27, 2022—(BRONX, NY)—Scientists, venture investment firm leaders, and industry stakeholders gathered on Tuesday, June 7 to attend… Continue reading Einstein Hosts Inaugural Therapeutics Venture and Pitch CompetitionRead Article
Orange Grove Bio Appoints Key Leadership & New Academic Collaboration
The University of Pittsburgh and Orange Grove Bio Establish Partnership… The following excerpt was taken from Globe Newswire — continue reading here. Orange Grove Bio, a preclinical drug investment and development firm, today announced several key leadership appointments highlighted by its naming John C. Byrd, M.D. Orange Grove Bio, a preclinical drug investment and development… Continue reading Orange Grove Bio Appoints Key Leadership & New Academic CollaborationRead Article
From The Patient's Eyes Podcast
From The Patient’s Eyes: Erin Schwindenhammer
Erin Schwindenhammer, a patient diagnosed with autoimmune diseases.Listen
From The Patient’s Eyes: Adriana Trama
Adriana Trama, a patient suffering from Crohn’s Disease and Ulcerative Colitis.Listen
From The Patient’s Eyes: Julianne Larkin
Julianne Larkin, a patient suffering from Graves’ disease and arthritis.Listen